The biosensors market focused on drug discovery and development is projected to grow at an annualized rate of 9% during the period 2022-2035, claims Roots Analysis

Published: December 2022

In recent years, the use of biosensors in drug discovery has been on the rise, driven by several technological advancements and the growing demand for inexpensive and effective techniques for analyzing potential drug candidates

Roots Analysis has announced the addition of “Biosensors Market: Focus on Drug Discovery and Drug Development, 2022 - 2035” report to its list of offerings.

A number of drug developers are already using novel biosensors for various drug discovery applications to address the concerns associated with high rate of failures of drug development programs and requirement of high capital investments. As the adoption of biosensors, specifically for drug discovery, increases amongst innovators in the pharma and biopharma industry, lucrative opportunities are expected to be created for players engaged in the biosensors for drug discovery market.

To order this 200+ page report, which features 85+ figures and 110+ tables, please visit

Key Market Insights 

Currently, more than 80 biosensors are being developed by various stakeholders, across the world 
Majority of the biosensors (64%) engaged in this domain are optical biosensors, followed by electrochemical biosensors (25%), quartz crystal microbalance biosensors (5%) and thermal biosensors (5%). Close to 95% of the biosensors are used for lead identification step in drug discovery. Further, 15% of the biosensors claim to support all the steps in drug discovery.

Over USD 1.2 billion invested in various domain focused initiatives, since 2018
Specifically, in 2021, industry players raised close to USD 600 billion. In addition, majority of the companies (66%) primarily received funding through venture capital rounds. Further, around 60% of the total funding instances were reported by players headquartered in the US.

In recent years, several global events related to biosensors in drug discovery were organized
Majority of the events related to biosensors in drug discovery were organized in Europe (45%). It is worth highlighting that the main agenda of these events was to discuss the development and challenges associated with the biosensors in drug discovery domain.

370+ patents related to biosensors in drug discovery have been granted / filed between 2018-2022
R&D activity related to biosensors in drug discovery is largely concentrated in North America, considering the fact that 70% of the total number of patents were filed in this region. In addition, most of the patents in this domain are granted patents (55%), followed by patent applications (44%).

North America and Europe are anticipated to capture over 70% of the market share, by 2035
In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (10%) in the long term. Further, in 2035, biosensors market for drug discovery applications for academic / research institutes is expected to capture the majority share (~60%) of the total market. 

To request a sample copy / brochure of this report, please visit

Key Questions Answered
  • Who are the key players engaged in the biosensors in drug discovery market?
  • What is the relative competitiveness of different biosensors being developed for drug discovery applications?
  • What are the key agenda items being discussed in various global events / conferences related to biosensors in drug discovery?
  • What is the focus area of the ongoing research activity related to biosensors in drug discovery?
  • How is the intellectual property landscape for biosensors in drug discovery likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

The financial opportunity within the biosensors in drug discovery market has been analyzed across the following segments:

  • Type of Biosensor
    • Optical
    • Electrochemical
    • Thermal
    • Others
  • Type of End User
    • Academic / Research Institutes
    • Industry Players
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • MENA
    • Rest of the World 

The report features inputs from eminent industry stakeholders, according to whom, continuous growth of biosensors market for drug discovery applications is primarily driven by the increasing adoption for such products. The report includes detailed transcripts of discussions held with the following experts:

  • Bill Rader (Chief Executive Officer, Efferent Labs)
  • Anne Marie Quinn (Chief Executive Officer, Montana Molecular)
  • Laurent Sabbagh (Associate Director and Head of Biology, Domain Therapeutics).

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its biosensor product portfolio, recent developments and an informed future outlook.

  • Agilent Technologies 
  • Axion Biosciences 
  • BioNavigations
  • Creoptix  
  • Cytiva
  • Dynamic Biosensors
  • Malvern Panalytical
  • Microvacuum
  • Sartorius
  • Tempo Bioscience 

For additional details, please visit or email 

You may also be interested in the following titles: 

  1. The Vaccine Adjuvants Market: Industry Trends and Global Forecasts, 2022-2035
  2. RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
  3. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035
  4. Aptamers: Therapeutics, Technologies and Services Market: Industry Trends and Global Forecasts, 2022-2035
  5. Subcutaneous Biologics, Technologies and Drug Delivery Systems Market: Industry Trends and Global Forecasts, 2022-2035
  6. Next Generation Complement Therapeutics Market: Industry Trends and Global Forecasts, 2022-2035

Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091


  • why-choose

    We are your partners with no equity

  • budget

    We fit in your budget

  • love

    We love what we do

  • treat

    Chance to prove ourselves

  • quality

    Best in class quality of work

  • trusted

    Most trusted consulting partner in the industry